609 related articles for article (PubMed ID: 15294456)
21. H3-receptor antagonists: synthesis and structure-activity relationships of para- and meta-substituted 4(5)-phenyl-2-[[2-[4(5)-imidazolyl]ethyl]thio]imidazoles.
Mor M; Bordi F; Silva C; Rivara S; Crivori P; Plazzi PV; Ballabeni V; Caretta A; Barocelli E; Impicciatore M; Carrupt PA; Testa B
J Med Chem; 1997 Aug; 40(16):2571-8. PubMed ID: 9258364
[TBL] [Abstract][Full Text] [Related]
22. A Novel Potent and Selective Histamine H
Hino N; Marumo T; Kotani M; Shimazaki T; Kaku-Fukumoto A; Hikichi H; Karasawa JI; Tomishima Y; Komiyama H; Tatsuda E; Nozawa D; Nakamura T; Chaki S
J Pharmacol Exp Ther; 2020 Nov; 375(2):276-285. PubMed ID: 32862143
[TBL] [Abstract][Full Text] [Related]
23. Synthesis and structure-activity relationships for biphenyl H3 receptor antagonists with moderate anti-cholinesterase activity.
Morini G; Comini M; Rivara M; Rivara S; Bordi F; Plazzi PV; Flammini L; Saccani F; Bertoni S; Ballabeni V; Barocelli E; Mor M
Bioorg Med Chem; 2008 Dec; 16(23):9911-24. PubMed ID: 18976927
[TBL] [Abstract][Full Text] [Related]
24. Sensitivity of histamine H3 receptor agonist-stimulated [35S]GTP gamma[S] binding to pertussis toxin.
Clark EA; Hill SJ
Eur J Pharmacol; 1996 Jan; 296(2):223-5. PubMed ID: 8838460
[TBL] [Abstract][Full Text] [Related]
25. Compared pharmacology of human histamine H3 and H4 receptors: structure-activity relationships of histamine derivatives.
Gbahou F; Vincent L; Humbert-Claude M; Tardivel-Lacombe J; Chabret C; Arrang JM
Br J Pharmacol; 2006 Apr; 147(7):744-54. PubMed ID: 16432504
[TBL] [Abstract][Full Text] [Related]
26. The histamine H3 receptor antagonist clobenpropit enhances GABA release to protect against NMDA-induced excitotoxicity through the cAMP/protein kinase A pathway in cultured cortical neurons.
Dai H; Fu Q; Shen Y; Hu W; Zhang Z; Timmerman H; Leurs R; Chen Z
Eur J Pharmacol; 2007 Jun; 563(1-3):117-23. PubMed ID: 17350613
[TBL] [Abstract][Full Text] [Related]
27. Sch 50971, an orally active histamine H3 receptor agonist, inhibits central neurogenic vascular inflammation and produces sedation in the guinea pig.
McLeod RL; Aslanian R; del Prado M; Duffy R; Egan RW; Kreutner W; McQuade R; Hey JA
J Pharmacol Exp Ther; 1998 Oct; 287(1):43-50. PubMed ID: 9765320
[TBL] [Abstract][Full Text] [Related]
28. [125I]iodoproxyfan and related compounds: a reversible radioligand and novel classes of antagonists with high affinity and selectivity for the histamine H3 receptor.
Stark H; Purand K; Hüls A; Ligneau X; Garbarg M; Schwartz JC; Schunack W
J Med Chem; 1996 Mar; 39(6):1220-6. PubMed ID: 8632428
[TBL] [Abstract][Full Text] [Related]
29. Search for novel leads for histamine H3-receptor antagonists: oxygen-containing derivatives.
Stark H; Hüls A; Ligneau X; Arrang JM; Schwartz JC; Schunack W
Pharmazie; 1997 Jul; 52(7):495-500. PubMed ID: 9266588
[TBL] [Abstract][Full Text] [Related]
30. Influence of a selective histamine H3 receptor antagonist on hypothalamic neural activity, food intake and body weight.
Malmlöf K; Zaragoza F; Golozoubova V; Refsgaard HH; Cremers T; Raun K; Wulff BS; Johansen PB; Westerink B; Rimvall K
Int J Obes (Lond); 2005 Dec; 29(12):1402-12. PubMed ID: 16151415
[TBL] [Abstract][Full Text] [Related]
31. Histamine H3 and dopamine D2 receptor-mediated [35S]GTPgamma[S] binding in rat striatum: evidence for additive effects but lack of interactions.
Humbert-Claude M; Morisset S; Gbahou F; Arrang JM
Biochem Pharmacol; 2007 Apr; 73(8):1172-81. PubMed ID: 17306767
[TBL] [Abstract][Full Text] [Related]
32. A robust and high-capacity [(35)S]GTPgammaS binding assay for determining antagonist and inverse agonist pharmacological parameters of histamine H(3) receptor ligands.
Miller TR; Baranowski JL; Estvander BR; Witte DG; Carr TL; Manelli AM; Krueger KM; Cowart MD; Brioni JD; Esbenshade TA
Assay Drug Dev Technol; 2008 Jun; 6(3):339-49. PubMed ID: 18593375
[TBL] [Abstract][Full Text] [Related]
33. Histamine homologues discriminating between two functional H3 receptor assays. Evidence for H3 receptor heterogeneity?
Leurs R; Kathmann M; Vollinga RC; Menge WM; Schlicker E; Timmerman H
J Pharmacol Exp Ther; 1996 Mar; 276(3):1009-15. PubMed ID: 8786529
[TBL] [Abstract][Full Text] [Related]
34. Development of trans-2-[1H-imidazol-4-yl] cyclopropane derivatives as new high-affinity histamine H3 receptor ligands.
Tedford CE; Phillips JG; Gregory R; Pawlowski GP; Fadnis L; Khan MA; Ali SM; Handley MK; Yates SL
J Pharmacol Exp Ther; 1999 May; 289(2):1160-8. PubMed ID: 10215700
[TBL] [Abstract][Full Text] [Related]
35. Unexpected partial H1-receptor agonism of imidazole-type histamine H3-receptor antagonists lacking a basic side chain.
Sadek B; Elz S; Pertz HH; Stark H; Schunack W
Inflamm Res; 2004 Aug; 53 Suppl 2():S109-15. PubMed ID: 15338060
[TBL] [Abstract][Full Text] [Related]
36. Substituted N-phenylcarbamates as histamine H3 receptor antagonists with improved in vivo potency.
Reidemeister S; Stark H; Ligneau X; Ganellin CR; Schwartz JC; Schunack W
Pharmazie; 2000 Feb; 55(2):83-6. PubMed ID: 10723763
[TBL] [Abstract][Full Text] [Related]
37. 4-Alkynylphenyl imidazolylpropyl ethers as selective histamine H3-receptor antagonists with high oral central nervous system activity.
Krause M; Ligneau X; Stark H; Garbarg M; Schwartz JC; Schunack W
J Med Chem; 1998 Oct; 41(21):4171-6. PubMed ID: 9767653
[TBL] [Abstract][Full Text] [Related]
38. GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models.
Medhurst AD; Atkins AR; Beresford IJ; Brackenborough K; Briggs MA; Calver AR; Cilia J; Cluderay JE; Crook B; Davis JB; Davis RK; Davis RP; Dawson LA; Foley AG; Gartlon J; Gonzalez MI; Heslop T; Hirst WD; Jennings C; Jones DN; Lacroix LP; Martyn A; Ociepka S; Ray A; Regan CM; Roberts JC; Schogger J; Southam E; Stean TO; Trail BK; Upton N; Wadsworth G; Wald JA; White T; Witherington J; Woolley ML; Worby A; Wilson DM
J Pharmacol Exp Ther; 2007 Jun; 321(3):1032-45. PubMed ID: 17327487
[TBL] [Abstract][Full Text] [Related]
39. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF).
Merlos M; Giral M; Balsa D; Ferrando R; Queralt M; Puigdemont A; García-Rafanell J; Forn J
J Pharmacol Exp Ther; 1997 Jan; 280(1):114-21. PubMed ID: 8996188
[TBL] [Abstract][Full Text] [Related]
40. Replacement of imidazole by a piperidine moiety differentially affects the potency of histamine H3-receptor antagonists.
Liedtke S; Flau K; Kathmann M; Schlicker E; Stark H; Meier G; Schunack W
Naunyn Schmiedebergs Arch Pharmacol; 2003 Jan; 367(1):43-50. PubMed ID: 12616340
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]